COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00098852
Recruitment Status : Unknown
Verified January 2009 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : December 9, 2004
Last Update Posted : January 6, 2014
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine.

PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Drug: rosiglitazone maleate Phase 2

Detailed Description:



  • Determine complete response in patients with locoregionally extensive or metastatic differentiated thyroid cancer treated with rosiglitazone.


  • Compare the long-term response of patients treated with this drug with historical controls.
  • Determine the toxicity profile of this drug in these patients.
  • Determine the presence/persistence of tumor in patients treated with this drug.
  • Determine the quality of life of patients treated with this drug.
  • Determine overall survival of patients treated with this drug.

OUTLINE: This is a pilot study.

Patients receive oral rosiglitazone once daily on weeks 1-8. Patients also receive oral liothyronine sodium twice daily on weeks 1-6 in preparation for radioactive iodine scan. Treatment continues in the absence of disease progression or unacceptable toxicity. At week 8, all patients undergo whole body radioactive iodine scan followed by a treatment dose of radioiodine to assess radioiodine uptake by tumor.

Quality of life is assessed at baseline and at the end of study treatment.

Patients are followed at 2 weeks, 1, 4, and 10 months, and then every 6 months for 1 year.

PROJECTED ACCRUAL: A total of 20-25 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Primary Purpose: Treatment
Official Title: A Pilot Study of Rosiglitazone in Patients With Incurable Differentiated Thyroid Cancer
Study Start Date : October 2004
Estimated Primary Completion Date : June 2010

Primary Outcome Measures :
  1. Radioiodine uptake and thyroglobulin level at 6 months and 1 year

Secondary Outcome Measures :
  1. Side effects of drug at 2 months

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of differentiated thyroid cancer

    • Locoregionally extensive and/or metastatic disease
    • Inoperable disease
  • Failed prior conventional therapy that included total/near-total thyroidectomy AND radioactive iodine I 131 ablation therapy
  • Elevated thyroglobulin (Tg) levels (> 3 ng/mL on thyroid hormone OR > 10 ng/mL off thyroid hormone)

    • Tg-antibody positive patients are eligible despite the Tg level
  • Radioactive iodine (RAI) scan showing no or therapeutically insignificant (< 1%) RAI uptake after thyroid hormone withdrawal

    • Scan performed within the past 18 months



  • 18 and over

Performance status

  • Not specified

Life expectancy

  • Not specified


  • Hemoglobin ≥ 10 g/dL
  • WBC ≥ 3,000/mm^3
  • Platelet count ≥ 50,000/mm^3


  • ALT ≤ 2 times upper limit of normal


  • Creatinine ≤ 1.5 mg/dL


  • No New York Heart Association class III or IV cardiac disease


  • Not pregnant
  • No nursing within the past 3 months
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No allergy to thiazolidinediones
  • No other malignancy except basal cell skin cancer


Biologic therapy

  • Not specified


  • More than 3 months since prior chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • No concurrent levothyroxine


  • See Disease Characteristics
  • No prior cumulative dose of radioiodine ≥ 800 mCi
  • Prior adjuvant or therapeutic external beam radiotherapy allowed


  • See Disease Characteristics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00098852

Layout table for location information
United States, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94115
Sponsors and Collaborators
University of California, San Francisco
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Electron Kebebew, MD University of California, San Francisco
Publications of Results:
Kebebew E, Reiff E, Greenspan FS, et al.: Rosiglitazone treatment induces radioiodine uptake in some patients with radioiodine-negative thyroglobulin-positive differentiated thyroid cancer. [Abstract] The Endocrine Society's 87th Annual Meeting, 4-7 June 2005, San Diego, CA. A-P3-573, 2005. Also available online. Last accessed February 21, 2006.

Layout table for additonal information
Responsible Party: Electron Kebebew, UCSF Helen Diller Family Comprehensive Cancer Center Identifier: NCT00098852    
Other Study ID Numbers: CDR0000398114
First Posted: December 9, 2004    Key Record Dates
Last Update Posted: January 6, 2014
Last Verified: January 2009
Keywords provided by National Cancer Institute (NCI):
recurrent thyroid cancer
stage II follicular thyroid cancer
stage IV follicular thyroid cancer
stage II papillary thyroid cancer
stage IV papillary thyroid cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Hypoglycemic Agents
Physiological Effects of Drugs